Overview

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC